lomonitinib   Click here for help

GtoPdb Ligand ID: 13750

Synonyms: ZE46-0134
Compound class: Synthetic organic
Comment: Lomonitinib is the INN for a tyrosine kinase inhibitor with antineoplastic potential. It appears to be the INN for Eilean Therapeutics' pan-FLT3/IRAK4 inhibitor (ZE46-0134) that is designed to simultaneously target clinically relevant resistance and activating FLT3 mutations and putative escape pathways (that arise via activation of IRAK4) in advanced AML [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 58.45
Molecular weight 436.51
XLogP 1.78
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC1=C(C=C(C=C1)C2=NN(C3=CC=C4CCNCC4=C3)C5=C2C=NC6=C5C=CC=C6)OC
Isomeric SMILES COC=1C=C(C=CC1OC)C2=NN(C3=C2C=NC=4C=CC=CC34)C5=CC=C6CCNCC6=C5
InChI InChI=1S/C27H24N4O2/c1-32-24-10-8-18(14-25(24)33-2)26-22-16-29-23-6-4-3-5-21(23)27(22)31(30-26)20-9-7-17-11-12-28-15-19(17)13-20/h3-10,13-14,16,28H,11-12,15H2,1-2H3
InChI Key AAIAGDXMETYTJE-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Lomonitinib (ZE46-0134) is a clinical candidate for the treatment of relapsed/refractory AML with FLT3 mutations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06366789 Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia Phase 1 Interventional Eilean Therapeutics
NCT06399315 Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers Phase 1 Interventional Eilean Therapeutics 1